Literature DB >> 32108049

Lipids and ketones dominate metabolism at the expense of glucose control in pulmonary arterial hypertension: a hyperglycaemic clamp and metabolomics study.

Jacob T Mey1,2, Adithya Hari2, Christopher L Axelrod1,2,3, Ciarán E Fealy2,4,5, Melissa L Erickson1,2, John P Kirwan1,2,5, Raed A Dweik2,6, Gustavo A Heresi7,6.   

Abstract

Individuals with idiopathic pulmonary arterial hypertension (PAH) display reduced oral glucose tolerance. This may involve defects in pancreatic function or insulin sensitivity but this hypothesis has not been tested; moreover, fasting nutrient metabolism remains poorly described in PAH. Thus, we aimed to characterise fasting nutrient metabolism and investigated the metabolic response to hyperglycaemia in PAH.12 participants (six PAH, six controls) were administered a hyperglycaemic clamp, while 52 (21 PAH, 31 controls) underwent plasma metabolomic analysis. Glucose, insulin, C-peptide, free fatty acids and acylcarnitines were assessed from the clamp. Plasma metabolomics was conducted on fasting plasma samples.The clamp verified a reduced insulin response to hyperglycaemia in PAH (-53% versus control), but with similar pancreatic insulin secretion. Skeletal muscle insulin sensitivity was unexpectedly greater in PAH. Hepatic insulin extraction was elevated in PAH (+11% versus control). Plasma metabolomics identified 862 metabolites: 213 elevated, 145 reduced in PAH (p<0.05). In both clamp and metabolomic cohorts, lipid oxidation and ketones were elevated in PAH. Insulin sensitivity, fatty acids, acylcarnitines and ketones correlated with PAH severity, while hepatic extraction and fatty acid:ketone ratio correlated with longer six-min walk distance.Poor glucose control in PAH could not be explained by pancreatic β-cell function or skeletal muscle insulin sensitivity. Instead, elevated hepatic insulin extraction emerged as an underlying factor. In agreement, nutrient metabolism in PAH favours lipid and ketone metabolism at the expense of glucose control. Future research should investigate the therapeutic potential of reinforcing lipid and ketone metabolism on clinical outcomes in PAH.
Copyright ©ERS 2020.

Entities:  

Year:  2020        PMID: 32108049      PMCID: PMC7263739          DOI: 10.1183/13993003.01700-2019

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  49 in total

1.  Five-Year outcomes of patients enrolled in the REVEAL Registry.

Authors:  Harrison W Farber; Dave P Miller; Abby D Poms; David B Badesch; Adaani E Frost; Erwan Muros-Le Rouzic; Alain J Romero; Wade W Benton; C Gregory Elliott; Michael D McGoon; Raymond L Benza
Journal:  Chest       Date:  2015-10       Impact factor: 9.410

2.  Ethnic differences in insulin sensitivity, β-cell function, and hepatic extraction between Japanese and Caucasians: a minimal model analysis.

Authors:  Jonas B Møller; Chiara Dalla Man; Rune V Overgaard; Steen H Ingwersen; Christoffer W Tornøe; Maria Pedersen; Haruhiko Tanaka; Mitsuru Ohsugi; Kohjiru Ueki; Jan Lynge; Nina-Maria Vasconcelos; Bente K Pedersen; Takashi Kadowaki; Claudio Cobelli
Journal:  J Clin Endocrinol Metab       Date:  2014-08-13       Impact factor: 5.958

3.  Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension.

Authors:  M Humbert; O Sitbon; A Yaïci; D Montani; D S O'Callaghan; X Jaïs; F Parent; L Savale; D Natali; S Günther; A Chaouat; F Chabot; J-F Cordier; G Habib; V Gressin; Z-C Jing; R Souza; G Simonneau
Journal:  Eur Respir J       Date:  2010-06-18       Impact factor: 16.671

4.  Novel glucosensor for hypoglycemic detection localized to the portal vein.

Authors:  A L Hevener; R N Bergman; C M Donovan
Journal:  Diabetes       Date:  1997-09       Impact factor: 9.461

5.  Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis.

Authors:  Fernando Bril; Romina Lomonaco; Beverly Orsak; Carolina Ortiz-Lopez; Amy Webb; Fermin Tio; Joan Hecht; Kenneth Cusi
Journal:  Hepatology       Date:  2014-04-25       Impact factor: 17.425

6.  Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland.

Authors:  Yi Ling; Martin K Johnson; David G Kiely; Robin Condliffe; Charlie A Elliot; J Simon R Gibbs; Luke S Howard; Joanna Pepke-Zaba; Karen K K Sheares; Paul A Corris; Andrew J Fisher; James L Lordan; Sean Gaine; J Gerry Coghlan; S John Wort; Michael A Gatzoulis; Andrew J Peacock
Journal:  Am J Respir Crit Care Med       Date:  2012-07-12       Impact factor: 21.405

Review 7.  Fatty acids, obesity, and insulin resistance: time for a reevaluation.

Authors:  Fredrik Karpe; Julian R Dickmann; Keith N Frayn
Journal:  Diabetes       Date:  2011-10       Impact factor: 9.461

8.  Human PAH is characterized by a pattern of lipid-related insulin resistance.

Authors:  Anna R Hemnes; J Matthew Luther; Christopher J Rhodes; Jason P Burgess; James Carlson; Run Fan; Joshua P Fessel; Niki Fortune; Robert E Gerszten; Stephen J Halliday; Rezzan Hekmat; Luke Howard; John H Newman; Kevin D Niswender; Meredith E Pugh; Ivan M Robbins; Quanhu Sheng; Cyndya A Shibao; Yu Shyr; Susan Sumner; Megha Talati; John Wharton; Martin R Wilkins; Fei Ye; Chang Yu; James West; Evan L Brittain
Journal:  JCI Insight       Date:  2019-01-10

Review 9.  Emerging Metabolic Therapies in Pulmonary Arterial Hypertension.

Authors:  Lloyd D Harvey; Stephen Y Chan
Journal:  J Clin Med       Date:  2017-04-04       Impact factor: 4.241

10.  The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense.

Authors:  Julie L Horton; Michael T Davidson; Clara Kurishima; Rick B Vega; Jeffery C Powers; Timothy R Matsuura; Christopher Petucci; E Douglas Lewandowski; Peter A Crawford; Deborah M Muoio; Fabio A Recchia; Daniel P Kelly
Journal:  JCI Insight       Date:  2019-02-21
View more
  8 in total

1.  Insulin Resistance Is Associated with Right Ventricular Dysfunction.

Authors:  Jeff Min; Mary E Putt; Wei Yang; Nadine Al-Naamani; Alain G Bertoni; Joao A C Lima; R Graham Barr; Lauren Beussink-Nelson; Sanjiv J Shah; Steven M Kawut; Benjamin H Freed
Journal:  Ann Am Thorac Soc       Date:  2022-04

Review 2.  A systematic review with meta-analysis of biomarkers for detection of pulmonary arterial hypertension.

Authors:  A Josien Smits; Liza Botros; Marijke A E Mol; Kirsten A Ziesemer; Martin R Wilkins; Anton Vonk Noordegraaf; Harm Jan Bogaard; Jurjan Aman
Journal:  ERJ Open Res       Date:  2022-05-30

3.  β-Hydroxybutyrate is reduced in humans with obesity-related NAFLD and displays a dose-dependent effect on skeletal muscle mitochondrial respiration in vitro.

Authors:  Jacob T Mey; Melissa L Erickson; Christopher L Axelrod; William T King; Chris A Flask; Arthur J McCullough; John P Kirwan
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-05-12       Impact factor: 4.310

Review 4.  Integrative Omics to Characterize and Classify Pulmonary Vascular Disease.

Authors:  Jane A Leopold; Anna R Hemnes
Journal:  Clin Chest Med       Date:  2021-01-12       Impact factor: 2.878

Review 5.  Liver abnormalities in pulmonary arterial hypertension.

Authors:  Nils P Nickel; Gian M Galura; Marc J Zuckerman; M Nawar Hakim; Haider Alkhateeb; Debabrata Mukherjee; Eric D Austin; Gustavo A Heresi
Journal:  Pulm Circ       Date:  2021-10-21       Impact factor: 3.017

Review 6.  The Glycobiology of Pulmonary Arterial Hypertension.

Authors:  Shia Vang; Phillip Cochran; Julio Sebastian Domingo; Stefanie Krick; Jarrod Wesley Barnes
Journal:  Metabolites       Date:  2022-04-01

Review 7.  Exercise metabolomics in pulmonary arterial hypertension: Where pulmonary vascular metabolism meets exercise physiology.

Authors:  Michael H Lee; Thaís C F Menezes; Julie A Reisz; Eloara V M Ferreira; Brian B Graham; Rudolf K F Oliveira
Journal:  Front Physiol       Date:  2022-09-12       Impact factor: 4.755

Review 8.  Important Functions and Molecular Mechanisms of Mitochondrial Redox Signaling in Pulmonary Hypertension.

Authors:  Jorge Reyes-García; Abril Carbajal-García; Annarita Di Mise; Yun-Min Zheng; Xiangdong Wang; Yong-Xiao Wang
Journal:  Antioxidants (Basel)       Date:  2022-02-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.